Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors.
about
EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer.Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorshipFocal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung CancerIs There a Survival Benefit of First-Line Epidermal Growth Factor Receptor Tyrosine-Kinase Inhibitor Monotherapy Versus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer?: A Meta-Analysis.Protein kinase inhibitor-induced endothelial cell cytotoxicity and its prediction based on calculated molecular descriptors.Intratumoral distribution of EGFR mutations and copy number in metastatic lung cancer, what impact on the initial molecular diagnosis?21st Century Cardio-Oncology: Identifying Cardiac Safety Signals in the Era of Personalized Medicine.Epidemiology of lung cancer prognosis: quantity and quality of life.The genomic landscape of TP53 and p53 annotated high grade ovarian serous carcinomas from a defined founder population associated with patient outcome.The correlation of expression of VEGF and EGFR with SUV of (18)FDG-PET-CT in non-small cell lung cancerEpidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma.Lymphoblastoid cell lines in pharmacogenomic discovery and clinical translationSimultaneous and rapid determination of gefitinib, erlotinib and afatinib plasma levels using liquid chromatography/tandem mass spectrometry in patients with non-small-cell lung cancer.Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancerFrequency of EGFR and KRAS mutations in lung adenocarcinomas in African AmericansEGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort.Incidence and survival of non-small cell lung cancer in Shanghai: a population-based cohort study.Patients harboring epidermal growth factor receptor (EGFR) double mutations had a lower objective response rate than those with a single mutation in non-small cell lung cancer when treated with EGFR-tyrosine kinase inhibitors.The HapMap Resource is Providing New Insights into Ourselves and its Application to Pharmacogenomics.The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancerEvaluation of genetic variation contributing to differences in gene expression between populationsEGFR, KRAS, BRAF, and HER-2 molecular status in brain metastases from 77 NSCLC patientsFrequency of EGFR and KRAS mutations in patients with non small cell lung cancer by racial background: do disparities exist?Analysis of the frequency of EGFR, KRAS and ALK mutations in patients with lung adenocarcinoma in Croatia.Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium.Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy.Racial/Ethnic Disparities in Genomic SequencingA retrospective analysis in patients with EGFR-mutant lung adenocarcinoma: is EGFR mutation associated with a higher incidence of brain metastasis?Supporting Asian patients with metastatic breast cancer during ixabepilone therapy.Global experience with ixabepilone in breast cancer.Biopsies: next-generation biospecimens for tailoring therapy.Epidermal growth factor receptor tyrosine-kinase inhibitor treatment resistance in non-small cell lung cancer: biological basis and therapeutic strategies.Insertion/deletion polymorphisms are convenient and reliable markers to assess chromosomal instability in human tumors.Docosahexaenoic acid alters epidermal growth factor receptor-related signaling by disrupting its lipid raft association.Analysis of population-specific pharmacogenomic variants using next-generation sequencing data.Assessment of DDR2, BRAF, EGFR and KRAS mutations as therapeutic targets in non-adenocarcinoma lung cancer patients.[The predictive value of EGFR status in non-small cell lung cancer patients treated with EGFR-TKIs].Epidemiology of non-small cell lung cancer in Asian Americans: incidence patterns among six subgroups by nativity.Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer.
P2860
Q27851583-2D2DF972-90A9-4785-B8AA-2B67BBE5FC45Q28278682-703DF615-4607-4D92-8335-23E0A08D7034Q28550689-41F5872C-C0EB-4913-8844-EDE9885E7F88Q33423782-549E39F9-3182-4255-B1B9-77BCA3812848Q33466404-B2C6F396-C3F9-41F6-A4E9-AC96E783E8A6Q33700689-5C5F6F48-D686-4F28-BC38-D6284188D907Q33900003-E78C6BB7-2EC9-4471-B988-4D3A7011662AQ34135295-560A2411-C217-4AFD-83E5-A83D538EBF12Q34429176-894FBDDA-0AD5-4E2D-B1D2-088936D8FF54Q34589126-2877B5B0-D1E3-4B08-B500-A409EB212571Q35345217-45893969-D998-4FC1-8092-2AA9C780FABDQ35799841-300D3C4A-592B-4243-B8BC-3A273E48CF5AQ35829430-8A45FEED-3178-4D1B-98A0-E6E056DB051AQ35898597-81BECF38-FFE5-47B7-BD4C-5793D24B95D1Q35915133-6061D2CB-92A6-4C36-B3C7-6E7686DB5F38Q36048238-86D80232-2A97-4FF3-9325-DF387D154D1FQ36406111-68E42957-3805-4BF4-90AD-36A86F01BACCQ36439392-A7C66434-3E6A-4C34-94A0-DED1006F6652Q36528253-C4FF69F9-D92E-4A87-9643-437A944ADA7DQ36545162-2BC7ED90-DE93-4723-8A6A-DA5576CB408DQ36610717-26E34B05-C495-4E55-85B9-A05252784F2BQ36718956-EDB0B615-7286-413E-AD7C-84B32441DDCEQ36977414-3A2ECF7E-1F35-439B-805A-DCEA39AFBB9DQ37110396-9658E56B-858A-4C2F-8068-E6441BA690A5Q37272817-0208D7BC-FDF8-4DA3-B38B-46420E83239DQ37288681-CA187E57-6B8A-4FA3-827F-05B2DE48CE83Q37414536-8FF244B5-A6B2-46AB-A3F8-AFCBE7590DA5Q37441661-0DCC58DD-74B4-44CD-A64F-9EFF6222C34BQ37636737-4B0D16A2-DEEB-408E-B2C3-5AF7FC0FC37DQ37682258-40AF208E-607B-4846-BE42-11C87755EEF5Q37873462-17C397F1-89D7-48BD-8231-3F4B74545379Q38116896-475493A1-D5CE-4756-8655-1C5786DC7FE9Q38168795-280D9CE8-81D0-405F-A7D4-625A36C6647BQ39609298-80371081-8B2D-4B9D-B70A-6E0D51986BE4Q39696487-5261BDDA-4E92-4952-9118-A563DC9B4D0BQ41606948-EAE32944-8CC4-4A62-9BF9-C6B26C736F60Q42204388-808B5C47-33C7-4D58-BAD2-9609DAB0711DQ42949613-BF1AA2BF-E14D-491A-967E-4CFB2B02558AQ44079965-AB52BFB2-9EA7-4F4E-A76A-D8F5A45639A5Q46195110-3A39AB73-9E34-4FCD-B20F-0D0777603386
P2860
Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Ethnic differences in response ...... or tyrosine kinase inhibitors.
@ast
Ethnic differences in response ...... or tyrosine kinase inhibitors.
@en
type
label
Ethnic differences in response ...... or tyrosine kinase inhibitors.
@ast
Ethnic differences in response ...... or tyrosine kinase inhibitors.
@en
prefLabel
Ethnic differences in response ...... or tyrosine kinase inhibitors.
@ast
Ethnic differences in response ...... or tyrosine kinase inhibitors.
@en
P356
P1476
Ethnic differences in response ...... or tyrosine kinase inhibitors.
@en
P2093
Emiliano Calvo
José Baselga
P304
P356
10.1200/JCO.2006.06.5961
P407
P577
2006-05-01T00:00:00Z